Radius Health ’s Tymlos (abaloparatide) Receives U.S. FDA Approval as a Treatment to Increase Bone Density in Men with Osteoporosis at High Risk for Fracture

Cambridge, Mass., December 20, 2022– Radius Health, Inc. (“Radius” or the“Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved Tymlos® (abaloparatide), a parathyroid hormone...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news